David M. O'Malley, MD, The Ohio State University

David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.

David M. O'Malley, MD, discusses the efficacy of pembrolizumab in patients with advanced ovarian cancer.

Experts give insight on what they are looking forward to in the endometrial cancer space.

Nicoletta Colombo, MD, PhD, reviews surgical advancements in endometrial cancer.

Experts in endometrial cancer comment on novel targets of interest that are currently being investigated.

Key opinion leaders take a look at the evolving treatment landscape in endometrial cancer, discussing ongoing trials in the space.

Experts discuss the importance of incorporating molecular features into the selection of adjuvant treatment.

Experts in endometrial cancer comment on therapeutic sequencing in endometrial cancer.

Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.

Experts give insight on their clinical use of pembrolizumab-lenvatinib. They highlight dose adjustments and the importance of the increased knowledge of adverse events.

Key opinion leaders discuss the presented data from Study 309/KEYNOTE-775, highlighting patient reported outcomes, safety, and dosing.

Vicky Makker, MD, presents the results from Study 309/KEYNOTE-775, as well as key safety findings.

Vicky Makker, MD, walks through the trial design of Study 309/KEYNOTE-775.

Experts review optimal approaches to treatment in advanced endometrial cancer, touching on clinical trial data.

Key opinion leaders share their thoughts on biomarker testing and multidisciplinary approaches for endometrial cancer at their institutions globally.

Experts in gynecologic cancer discuss the heterogeneity of endometrial cancer..